PYX-102 / Pyxis Oncology - LARVOL DELTA

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting (GlobeNewswire) - '"Data from PDX tumor preclinical models has shown potent anti-tumor activity in multiple human cancer indications. We will also demonstrate that the overexpression of EDB+FN, the molecular target of PYX-201, is consistently observed in various human tumor types, with minimal expression observed in healthy tissue. For our PYX-106 program, we will also present encouraging preclinical data supporting the clinical opportunity of this immune-oncology therapeutic candidate to potentially demonstrate clinical activity in individuals that are not candidates for anti-PD-(L)1 approaches. Finally, we will present anti-tumor efficacy data supporting the potential for PYX-102 as a therapeutic candidate, and remain open to out-licensing opportunities for future development.'"

Preclinical • Oncology • Solid Tumor

PYX-102, an anti-KLRG1 antibody, enhances cytotoxic activity of CD8-T-cells from PBMC and human tumor samples by blocking the interaction between KLRG1 and cadherins (SITC 2023) - "Tumor antigen-specific KLRG1+CD8-T-cells were observed in breast, lung, kidney, ovarian, esophageal and colorectal tumors which are known to express cadherins, strongly supporting the rational for targeting KLRG1+CD8-T-cells. Conclusions Our data on PYX-102, which blocks the KLRG1-cadherin interaction and leads to activation of CD8-T-cells, supports further development of this promising and innovative anti-cancer experimental therapeutic."

Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • CCR7 • CD8 • CDH1 • HER-2 • IFNG • KLRG1 • NCAM1 • TNFA

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 (GlobeNewswire) - "Pyxis Oncology, Inc...announced four abstracts for four different assets have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego....'We continue to expect to see preliminary data from this study, including biomarker results and early signs of potential clinical activity, in early 2024.'"

P1 data • Preclinical • Oncology • Solid Tumor

Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update (GlobeNewswire) - "Pyxis Oncology is on track to file Investigational New Drug applications (INDs) for PYX-201 and PYX-106 in 2022; The Company will pause the preclinical development of PYX-203 and PYX-102."

IND • Preclinical • Oncology

Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) - "Pyxis Oncology, Inc...today reported financial results for its first quarter ended March 31, 2022. The Company ended the quarter with approximately $247 million in cash and cash equivalents. Pyxis Oncology remains on target to file INDs for anti-EDB, PYX-201, and anti-Siglec-15, PYX-106, in the second half of 2022 and INDs for anti-CD123, PYX-203, and anti-KLRG1, PYX-102, in the second half of 2023. Further, as previously disclosed, the Company expects to provide an update on its anti-DLK1 ADC, PYX-202, in mid-2022."

IND • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Melanoma • Merkel Cell Carcinoma • Non Small Cell Lung Cancer • Non-melanoma Skin Cancer • Oncology • Ovarian Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer • Triple Negative Breast Cancer • Uterine Cancer